Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delayed-Release Risedronate vs Immediate-Release Risedronate in Postmenopausal Osteoporosis
NCT00541658Phase 3Completed
- Sponsor
- Warner Chilcott
- Start
- Oct 2007
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of risedronate in postmenopausal osteoporosis (3 arms), sponsored by Warner Chilcott. Primary endpoint: Percent Change From Baseline Lumbar Spine Bone Mineral Density at 52 weeks. Started Oct 2007; status: completed.
02
Drugs
risedronate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00541658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541658.